Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
Simple logic tells us that those atop a societal hierarchy will provide rewards for professionals—be they clergy or psychiatrists—who promote an ideology that maintains the status quo, and that the ruling class will do everything possible to manipulate the public to believe that the social-economic-political status quo is natural.
About 60% of the authors had financial ties to industry, which are not disclosed in the DSM. Studies show that conflicts of interest lead to pro-industry decision-making.
“. . . if the major media picks up on this story, they will have the chance to report on what arguably is the worst—and most harmful—scandal in American medical history”
Historically, there have always been some patients who report that any treatment for depression—including bloodletting—has worked for them, but science demands that for a treatment to be deemed truly effective, it must work better than a placebo or the passage of time without any treatment. This is especially important for antidepressant drugs—including Prozac, Zoloft, and other selective serotonin reuptake inhibitors (SSRIs), as well as Effexor, Cymbalta, and other serotonin and norepinephrine reuptake inhibitors (SNRIs)—because all of these drugs have uncontroversial troubling side effects.
The long simmering political crisis in Pakistan is now boiling over. Terrified that the campaign of ex-Prime Minister Imran Khan for immediate new elections could inadvertently precipitate an explosion of mass working class anger against brutal IMF-dictated austerity, soaring food prices and mass joblessness, the government and military are resorting to dictatorial forms of rule.
UN experts said this week that US sanctions on Iran are causing more deaths of Iranians with thalassemia, a congenital blood disorder that requires specialized medicine.
Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit the market. But do they have sufficient independence from the companies they are meant to regulate? Maryanne Demasi investigates
In Latin America pharmaceutical bullying went a notch higher. In addition to legal indemnity, Pfizer demanded protection against their own negligence and mistakes. Argentina amended its vaccine law, three times, yet Pfizer was not happy. Pfizer wanted Argentina’s bank reserves and military bases as “guarantees”.
In the era of neo-colonialism, Pharma industry was the new East India Company.
…
Despite such pressure, India did not succumb. Eventually, Pfizer withdrew its application in 2021 We continued our vaccine programme with drugs that complied with our legal requirements.
Ms. Cat’s Chronicles 
You must be logged in to post a comment.